{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:37:53Z","timestamp":1793144273387,"version":"4.5.0"},"reference-count":40,"publisher":"The Journal of Rheumatology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Antisynthetase syndrome (AS)-related interstitial lung disease (ILD) has a poor prognosis. Intravenous cyclophosphamide (IV CYC) and rituximab (RTX) are the main treatments currently used for moderate to severe ILD. Here, we compare the efficacy of CYC followed by standard immunosuppressive treatment (IST) versus RTX in AS-related ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational retrospective study was conducted between 2003 and 2016 in 3 tertiary care centers. All patients with AS-related ILD and treated with CYC or RTX with at least 6 months of follow-up were included. Pulmonary progression-free survival (PFS), defined according to the American Thoracic Society guidelines, was assessed at 6 months and 2 years. All severe adverse events (AE) were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty-two patients were included. Thirty-four patients received 2\u201312 monthly IV CYC pulses, followed by standard IST in 30 cases (88%). The RTX group included 28 patients. Following the initial Day 1 to Day 15 infusions, RTX was repeated every 6 months in 26 cases (93%) and 15 patients (54%) concomitantly received another IST. The median steroid dose was similar between both groups. Although RTX and CYC demonstrated similar PFS at 6 months (92% vs 85%, respectively), RTX was superior at 2 years (HR 0.263, 95% CI 0.094\u20130.732,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.011). Interestingly, lower diffusing lung capacity for carbon monoxide (DLCO) at baseline was independently predictive of poor 2-year PFS [0.965 (0.936\u20130.995),\n                      <jats:italic>P<\/jats:italic>\n                      = 0.023]. Forced vital capacity and DLCO improved in both groups without significant differences. Serious AE were similar in both groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite similar PFS at 6 months, RTX was associated with a better 2-year PFS compared to CYC in patients with AS-related ILD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.190505","type":"journal-article","created":{"date-parts":[[2020,3,15]],"date-time":"2020-03-15T12:25:13Z","timestamp":1584275113000},"page":"1678-1686","source":"Crossref","is-referenced-by-count":44,"title":["Rituximab and Cyclophosphamide in Antisynthetase Syndrome\u2013related Interstitial Lung Disease: An Observational Retrospective Study"],"prefix":"10.3899","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4078-6306","authenticated-orcid":false,"given":"Vincent","family":"Langlois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Gillibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1607-1407","authenticated-orcid":false,"given":"Yurdag\u00fcl","family":"Uzunhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Chabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oc\u00e9ane","family":"Landon-Cardinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuberaka","family":"Mariampillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Champtiaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilario","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Hervier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2020,3,15]]},"reference":[{"key":"2022062017050998000_47.11.1678.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.06.006"},{"key":"2022062017050998000_47.11.1678.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201800"},{"key":"2022062017050998000_47.11.1678.3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/qjmed\/77.1.1019","article-title":"Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes","volume":"77","author":"Marguerie","year":"1990","journal-title":"Q J Med"},{"key":"2022062017050998000_47.11.1678.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00156312"},{"key":"2022062017050998000_47.11.1678.5","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1097\/MD.0000000000000798","article-title":"Myocarditis in patients With antisynthetase syndrome: Prevalence, presentation, and outcomes","volume":"94","author":"Dieval","year":"2015","journal-title":"Medicine"},{"key":"2022062017050998000_47.11.1678.6","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv192"},{"key":"2022062017050998000_47.11.1678.7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/nan.12380","article-title":"Integrated classification of inflammatory myopathies","volume":"43","author":"Allenbach","year":"2017","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2022062017050998000_47.11.1678.8","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"2022062017050998000_47.11.1678.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.03.004"},{"key":"2022062017050998000_47.11.1678.10","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00026703"},{"key":"2022062017050998000_47.11.1678.11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung"},{"key":"2022062017050998000_47.11.1678.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.01.008"},{"key":"2022062017050998000_47.11.1678.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.23571"},{"key":"2022062017050998000_47.11.1678.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel112"},{"key":"2022062017050998000_47.11.1678.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121026"},{"key":"2022062017050998000_47.11.1678.16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21895"},{"key":"2022062017050998000_47.11.1678.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.02.015"},{"key":"2022062017050998000_47.11.1678.18","doi-asserted-by":"publisher","DOI":"10.1080\/08916930500124023"},{"key":"2022062017050998000_47.11.1678.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep455"},{"key":"2022062017050998000_47.11.1678.20","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","article-title":"Management of myositis-related interstitial lung disease","volume":"150","author":"Morisset","year":"2016","journal-title":"Chest"},{"key":"2022062017050998000_47.11.1678.21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/BOR.0000000000000270","article-title":"Management of connective tissue diseases associated interstitial lung disease: A review of the published literature","volume":"28","author":"Wallace","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2022062017050998000_47.11.1678.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.37754"},{"key":"2022062017050998000_47.11.1678.23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133702"},{"key":"2022062017050998000_47.11.1678.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev004"},{"key":"2022062017050998000_47.11.1678.25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/MJT.0000000000000245","article-title":"Successful treatment of life-threatening interstitial lung disease secondary to antisynthetase syndrome using rituximab: A case report and review of the literature","volume":"23","author":"Dasa","year":"2016","journal-title":"Am J Ther"},{"key":"2022062017050998000_47.11.1678.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew195"},{"key":"2022062017050998000_47.11.1678.27","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1148\/rg.2015140334","article-title":"American Thoracic Society-European Respiratory Society classification of the idiopathic interstitial pneumonias: Advances in knowledge since 2002","volume":"35","author":"Sverzellati","year":"2015","journal-title":"Radiographics"},{"key":"2022062017050998000_47.11.1678.28","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.191.2.8153310"},{"key":"2022062017050998000_47.11.1678.29","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2361031674"},{"key":"2022062017050998000_47.11.1678.30","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.2.ats3-00"},{"key":"2022062017050998000_47.11.1678.31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/thoraxjnl-2013-204202","article-title":"Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials","volume":"69","author":"Saketkoo","year":"2014","journal-title":"Thorax"},{"key":"2022062017050998000_47.11.1678.32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2022062017050998000_47.11.1678.33","unstructured":"Dolgin M Association NYH Fox AC Gorlin R Levin RI New York Heart Association . Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Lippincott Williams Wilkins; 1994."},{"key":"2022062017050998000_47.11.1678.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2014.11.026"},{"key":"2022062017050998000_47.11.1678.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213917"},{"key":"2022062017050998000_47.11.1678.36","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2213010158"},{"key":"2022062017050998000_47.11.1678.37","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology"},{"key":"2022062017050998000_47.11.1678.38","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew146"},{"key":"2022062017050998000_47.11.1678.39","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170541"},{"key":"2022062017050998000_47.11.1678.40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0761-8425(05)85433-6","article-title":"Compliance, therapeutic observance and therapeutic adherence: what do we speak about?","volume":"22","author":"Lamouroux","year":"2005","journal-title":"Rev Mal Respir"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.190505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T20:09:14Z","timestamp":1655755754000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.190505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,15]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,2]]},"published-print":{"date-parts":[[2020,11,1]]}},"alternative-id":["10.3899\/jrheum.190505"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.190505","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,15]]}}}